Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2025

Zhang Qian, Yang Yehao, Xie Mingying, Zhou Zichao, Wu Haicheng, Zhai Wanchen, Chen Yunfei, Chen Kaiyan, Zhou Shichao, Li Hui, Fan Yun

Abstract excerpt

BACKGROUND: Brain metastases (BM) represent a common complication in non-small-cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) mutations. We aimed to characterize the BM incidence and its association with genetic subtypes, and to analyze treatment outcomes and prognostic factors in this patient population. METHODS: Between July 2018 and July 2023, we retrospectively screened 6536...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Female
Lung Neoplasms
Male
Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Erb-b2 Receptor Tyrosine Kinases

Middle Aged

Prognosis

Aged

Mutation

Retrospective Studies

Adult

Aged, 80 and over

Follow-Up Studies

Source

Identifiers

PMID: 40480016
DOI: 10.1016/j.lungcan.2025.108616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.PMID 40480016Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.Semantic proximity Read ↗

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.Semantic proximity Read ↗

Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.Semantic proximity Read ↗

Converging Survival Trends in Non-Small Cell Lung Cancer Patients With and Without Brain Metastasis Receiving State-of-the-Art TreatmentSemantic proximity Read ↗

Genomic Analysis and Clinical Correlation of Non-Small Cell Lung Cancer with Special Reference to Brain Metastasis.Semantic proximity Read ↗

Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancersSemantic proximity Read ↗

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.Semantic proximity Read ↗

Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer.Semantic proximity Read ↗

Pembrolizumab plus bevacizumab achieves long-term progression free survival in patients with lung adenocarcinoma with brain metastases: a case report and literature reviewSemantic proximity Read ↗

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.